Pulse Biosciences Showcases Innovative nsPFA Technology at AF Symposium
Pulse Biosciences, Inc. (Nasdaq: PLSE), known for its innovative approach to bioelectric medicine, is excited to announce that its cutting-edge Nanosecond Pulsed Field Ablation™ (nsPFA™) technology will be prominently featured in various presentations at the upcoming Annual AF Symposium 2025. This event promises to be a pivotal moment for showcasing advancements in cardiac care technology.
Significance of nsPFA Technology
The nsPFA technology, designed to enhance the treatment of atrial fibrillation, utilizes a unique mechanism that distinguishes it from traditional ablation methods. Its applications are not only innovative but also provide significant clinical insights into improving patient outcomes.
Details of the Presentations
Throughout the symposium, especially during the late-breaking science session and live case transmissions, attendees will witness presentations from leading experts in the field. Key highlights include demonstrations of the nsPFA 360° catheter, which integrates seamlessly with the Abbott Ensite X 3D Mapping System.
Key Programming Highlights
Mark your calendars for January 17 and 18, as these are key dates to witness the advancements brought forth by Pulse Biosciences:
Friday, January 17
- 5:30-7:00 PM: Featuring Dr. Vivek Reddy in a Late Breaking Clinical Science Session.
- Title: Pulsed Field Ablation Using a Compliant Circular Catheter Delivering Nanosecond Pulses to Treat Atrial Fibrillation.
- The session will cover a feasibility study involving the nsPFA 360° Cardiac Catheter with insights from Drs. Vivek Reddy and Petr Neuzil alongside the first 30 patients treated.
Saturday, January 18
- 7:30-9:30 AM: Live Case Transmission by Dr. Petr Neuzil.
- Title: Nanosecond Pulsed Field Ablation for Atrial Fibrillation.
- The live case aims to demonstrate the workflow efficiency of the nsPFA 360° Catheter during pulmonary vein isolation and highlight its integration with the 3D mapping technology.
Expert Insights from Pulse Biosciences' Leadership
Paul LaViolette, Co-Chairman of Pulse Biosciences’ Board of Directors, shared his enthusiasm regarding the progress the team has made. His remarks emphasize the remarkable advancements in product development, reinforcing the clinical benefits associated with the nsPFA 360° Cardiac Catheter device. LaViolette noted, "Having two renowned physicians showcasing the clinical benefits is a strong testament to our team's dedication and the unique role of nsPFA in cardiac treatment." Furthermore, he outlined the company’s intentions to initiate a pivotal U.S. IDE clinical study for the catheter, aiming for mid-2025.
About Pulse Biosciences
Pulse Biosciences is at the forefront of medical innovation, devoted to pioneering health solutions that aim to enhance patients' quality of life. With its proprietary CellFX® nsPFA™ technology that delivers nanosecond pulses of electrical energy, the company effectively clears targeted cells while preserving nearby non-cellular tissue. This innovative approach showcases Pulse Biosciences' commitment to advancing healthcare and providing profound benefits to patients and healthcare providers alike.
Frequently Asked Questions
What is nsPFA technology?
nsPFA stands for Nanosecond Pulsed Field Ablation, an innovative technology used to treat atrial fibrillation by delivering nanosecond pulses of electrical energy.
Who will present the nsPFA technology at the symposium?
Dr. Vivek Reddy and Dr. Petr Neuzil will be presenting the nsPFA technology at the AF Symposium.
When will the AF Symposium take place?
The AF Symposium will be held from January 16-18 in 2025.
What is the goal of Pulse Biosciences' presentations?
The presentations aim to showcase the clinical benefits and innovative capabilities of the nsPFA technology in treating atrial fibrillation.
What are the future plans for nsPFA technology?
Pulse Biosciences aims to initiate a pivotal U.S. IDE clinical study for the nsPFA 360° catheter in mid-2025.